Providers/Grant Support
This activity is supported by an educational grant from Sun Pharmaceutical Industries Ltd.
Credits Available
- Physicians — maximum of 0.5 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Program Overview
This 20-minute case-based activity explores real-world presentations and management strategies for Alopecia areata, offering practical insights into diagnosis, treatment selection, and long-term care considerations. Learners will gain updates on emerging data and evolving therapeutic strategies to support sustained disease control and long-term management.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine clinical evidence for the use of Janus kinase (JAK) inhibitors in long-term management of alopecia areata (AA)
- Discuss strategies to optimize treatment of AA with approved JAK inhibitors using clinical evidence
Faculty
Adelaide Hebert, MD
Professor of Dermatology and Pediatrics
UTHealth McGovern Medical School
Houston, TX
Karan Lal, DO, MS, FAAD
Director of Pediatric and Cosmetic Dermatology
Affiliated Dermatology
Scottsdale, AZ
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Faculty Name
Adelaide A. Hebert, MD
Grant/Research Support: Pfizer, Arcutis, Lilly, AbbVie
Consultant: Pfizer, Arcutis, Almirall, Biofrontera, Galderma, Or
Speakers’ Bureau or Honoraria: Pfizer, Arcuits, Almirall, Incyte, Sun
Karan Lal, DO, MS, FAAD
Advisory Board/Consultant: Artics, Cerave, Eli Lilly, Galderma, Incyte, La Mer, LRP, Sun, Tiger Aesthetics
Speaker’s Bureau: AbbVie, Amgen, Arcutis, Galderma, Incyte, Lilly, Organon, Pfizer, Regeneron, Sanofi, Sun, Verrica
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
The Institute requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: Jlevine@cmesquared.org